SCHEMBL29913397

SCHEMBL29913397

Oc1cccc2c1C1(CC1)CO2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 1/20 0.32
ALDH1A1 P00352 1/20 0.32
EGFR P00533 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
LMNA P02545 1/20 0.32
FYN P06241 1/20 0.32
MMP2 P08253 1/20 0.32
MMP9 P14780 1/20 0.32
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
MMP8 P22894 1/20 0.32
CA6 P23280 1/20 0.32
CDK2 P24941 1/20 0.32
MMP12 P39900 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ADAMTS5 Q9UNA0 1/20 0.32
AKT1 P31749 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980294 1.00 ADAMTS4 (0.32) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL9904685 0.82 ITGB2 (0.38) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL21262971 0.79 ALDH1A1 (0.35) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL1764717 0.76 CNR1 (0.34) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL21116508 0.72 HTR1A (0.39) ALDH1A1CA1CA2HSD17B10TDP1
SCHEMBL31304774 0.70 PLK1 (0.41)
SCHEMBL18199055 0.69 TMEM97 (0.32)
SCHEMBL16661511 0.69 ITGB2 (0.37) LMNAAKT1ITGB2ICAM1ITGAL
SCHEMBL9904847 0.69 BCL2L1 (0.33) ADAMTS4ALDH1A1EGFRCA1CA2
SCHEMBL18025155 0.68 TSHR (0.36) CA1CA2LMNAALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 US disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 US disclosed
CN-115066424-B Kv3 modulators 奥蒂福尼疗法有限公司 2024-12-27 CN disclosed
CN-117751119-A Potassium channel modulators 奥蒂福尼疗法有限公司 2024-03-22 CN disclosed
WO-2023017263-A1 POTASSIUM CHANNEL MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-16 WO disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
CN-115066424-A Kv3 modulators 奥蒂福尼疗法有限公司 2022-09-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 ADAMTS4 4561/4885ALDH1A1 3109/4885EGFR 3926/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 ADAMTS4 4501/4885ALDH1A1 3250/4885EGFR 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.